Innovimmune Biotherapeutics is Drug Delivery in United States that focus on nuclear hormone business. Founded in 2010. They cover business area such as developer, immunomodulatory drug, autoimmune and oncologic disease, an innovative product pipeline, novel small molecule NME drug candidate, cytokine, chemokine, hormone, medical company, cancer disease.
2010
( 14 years old in 2024 )
Nuclear Hormone
-
125 Maiden Lane
New York, NY 10038
United States
Private
developerimmunomodulatory drugautoimmune and oncologic diseasean innovative product pipelinenovel small molecule NME drug candidatecytokinechemokinehormonemedical companycancer disease
* We use standard office opening hours in near Innovimmune Biotherapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Innovimmune Biotherapeutics is Drug Delivery business from United States that founded in 2010 (14 years old in 2024), Innovimmune Biotherapeutics business is focusing on Nuclear Hormone.
Innovimmune Biotherapeutics headquarter office and corporate office address is located in 125 Maiden Lane New York, NY 10038 United States.
Innovimmune Biotherapeutics was founded in United States.
In 2024, Innovimmune Biotherapeutics is currently focus on nuclear hormone sector.
Above is snippet of Google Trends for "nuclear hormone" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Innovimmune Biotherapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
